Cannabis Use Disorder

Signs, Symptoms & Evidence-Based Treatment

Understanding marijuana addiction: DSM-5 diagnostic criteria, prevalence data, withdrawal symptoms, and how to get help

Cannabis use disorder (CUD) is a clinically recognized condition in which an individual is unable to stop using cannabis despite significant negative consequences to their health, relationships, and daily functioning. Contrary to the widespread belief that marijuana is not addictive, decades of research demonstrate that cannabis can produce dependence, withdrawal, and compulsive use patterns that meet formal diagnostic criteria for a substance use disorder.

CUD Severity Classification

• Mild: 2-3 criteria met
• Moderate: 4-5 criteria met
• Severe: 6 or more criteria met

1. Using more than intended: Cannabis is often taken in larger amounts or over a longer period than was intended.
2. Inability to cut down: There is a persistent desire or unsuccessful efforts to cut down or control cannabis use.
3. Excessive time spent: A great deal of time is spent in activities necessary to obtain cannabis, use cannabis, or recover from its effects.
4. Craving: Craving, or a strong desire or urge to use cannabis.

5. Failure to fulfill obligations: Recurrent cannabis use resulting in a failure to fulfill major role obligations at work, school, or home.
6. Social/interpersonal problems: Continued cannabis use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of cannabis.
7. Activities given up: Important social, occupational, or recreational activities are given up or reduced because of cannabis use.

8. Physically hazardous use: Recurrent cannabis use in situations in which it is physically hazardous (e.g., driving while impaired).
9. Use despite known harm: Cannabis use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by cannabis.

10. Tolerance: Defined by either (a) a need for markedly increased amounts of cannabis to achieve intoxication or desired effect, or (b) a markedly diminished effect with continued use of the same amount of cannabis.
11. Withdrawal: Manifested by either (a) the characteristic cannabis withdrawal syndrome, or (b) cannabis (or a closely related substance) is taken to relieve or avoid withdrawal symptoms.

Clinical Note: The presence of craving (Criterion 4) was added in the DSM-5 and was not part of the older DSM-IV criteria. Cannabis withdrawal (Criterion 11) was also newly recognized as a formal diagnostic entity in the DSM-5, reflecting the growing body of evidence that cessation of heavy cannabis use produces a clinically significant withdrawal syndrome.

1. Frequency and Pattern of Use

Daily or near-daily cannabis use is the strongest predictor of developing CUD. People who use cannabis daily are significantly more likely to develop tolerance, experience withdrawal upon cessation, and lose control over their use compared to occasional users. The progression from occasional to daily use is often gradual and may go unnoticed.

2. Age of First Use

Earlier age of first cannabis use is strongly associated with higher rates of CUD. Individuals who begin using cannabis before age 18 -- and especially before age 15 -- face substantially elevated risk. The developing adolescent brain is particularly susceptible to the neuroadaptive changes that underlie addiction. This is why AACAP estimates that 1 in 6 adolescent users develops CUD, compared to lower rates among adults who initiate use later in life.

3. THC Potency

Higher-potency cannabis products accelerate the development of tolerance and dependence. With average THC content rising from 3.96% in 1995 to 16.14% in 2022, and concentrates reaching 60-90% THC, today's cannabis products carry substantially greater addiction potential than those available in previous decades. Research has demonstrated a dose-response relationship between THC exposure and the risk of developing CUD.

4. Family History and Genetics

Genetic factors account for an estimated 50-70% of the vulnerability to developing substance use disorders, including CUD. A family history of substance use disorders -- whether involving cannabis, alcohol, or other substances -- is a significant risk factor. Twin and adoption studies have consistently demonstrated a heritable component to cannabis use disorder.

5. Co-occurring Mental Health Conditions

Individuals with pre-existing mental health conditions -- including anxiety disorders, depression, PTSD, ADHD, and bipolar disorder -- are at elevated risk for developing CUD. Cannabis is frequently used as a form of self-medication for these conditions, which can rapidly escalate into problematic use patterns. Paradoxically, while cannabis may temporarily mask symptoms, it tends to worsen these underlying conditions over time, creating a cycle of increasing use and worsening mental health.

6. Social and Environmental Factors

Peer group cannabis use, easy access to cannabis products, living in states with legalized recreational cannabis, exposure to cannabis advertising, and low perception of risk all contribute to increased use and higher rates of CUD. Adolescents are particularly susceptible to social influences around cannabis use.

Common Cannabis Withdrawal Symptoms

• Day 1-3: Symptoms typically begin within 24-72 hours of last use. Irritability, anxiety, and insomnia are usually the first symptoms to appear.
• Days 4-7: Symptoms generally peak during the first week. Cravings, mood disturbance, and sleep difficulty are at their most intense.
• Week 2: Most acute symptoms begin to subside. Physical symptoms like appetite changes and sweating typically resolve first.
• Weeks 2-4: Psychological symptoms such as irritability and cravings may persist. Sleep disturbance can last several weeks.
• Beyond 4 weeks: Some individuals experience protracted withdrawal with mild symptoms lasting several months, particularly cravings and sleep disruption.

Cognitive Behavioral Therapy (CBT)

CBT is the most extensively studied treatment for CUD. It works by helping individuals identify and modify the thought patterns, beliefs, and behaviors that maintain cannabis use. Key components include:

• Identifying triggers for cannabis use (emotional, environmental, social)
• Developing coping strategies to manage cravings and high-risk situations
• Challenging cognitive distortions about cannabis use (e.g., "I need it to relax")
• Building skills for managing stress, anxiety, and negative emotions without cannabis
• Relapse prevention planning

Typical course: 8-12 sessions over 3-4 months. Can be delivered individually or in group formats.

Motivational Enhancement Therapy (MET)

MET is a brief, focused therapy designed to mobilize the individual's own internal motivation to change. Rather than prescribing change, the therapist uses motivational interviewing techniques to help the patient explore and resolve their ambivalence about cannabis use. MET is particularly effective for individuals who are not yet convinced they need to change.

• Expressing empathy and understanding the patient's perspective
• Developing discrepancy between current behavior and personal goals/values
• Rolling with resistance rather than confronting it
• Supporting self-efficacy and confidence in the ability to change

Typical course: 2-4 sessions. Often used as a first-line or adjunctive approach.

Contingency Management (CM)

Contingency management provides tangible, positive reinforcement for achieving specific treatment goals -- most commonly, verified abstinence from cannabis. Patients receive vouchers, prizes, or other incentives for negative drug tests. While the concept may sound simplistic, CM has a strong evidence base and produces some of the largest treatment effect sizes in substance use treatment.

• Rewards for verified abstinence (negative urine drug screens)
• Escalating incentive value for sustained abstinence
• Immediate positive reinforcement that competes with the reinforcing effects of cannabis

Most effective when combined with CBT or MET. Typically delivered over 8-12 weeks.

Combination Approaches Yield Best Outcomes

Research consistently shows that combining multiple evidence-based approaches produces better outcomes than any single intervention alone. The most studied and effective combination is CBT + MET + Contingency Management. This multimodal approach addresses motivation (MET), skill-building (CBT), and behavioral reinforcement (CM) simultaneously.

In the past 12 months, have you...

Important Disclaimer: This self-assessment is an educational tool based on DSM-5 criteria. It is not a diagnostic instrument. Only a qualified mental health professional can diagnose cannabis use disorder. If you are concerned about your cannabis use, please consult with a psychiatrist or other licensed clinician.

Seek evaluation if any of the following apply:

• You have tried to cut down or stop using cannabis on your own and have been unable to
• Your cannabis use is affecting your performance at work, school, or in your personal responsibilities
• You are using cannabis to manage anxiety, depression, insomnia, or other mental health symptoms
• People close to you -- family, friends, partner -- have expressed concern about your use
• You experience withdrawal symptoms (irritability, insomnia, appetite loss) when you stop
• You find yourself thinking about cannabis frequently or craving it when you cannot use
• You have noticed that you need significantly more cannabis to achieve the same effect
• Your cannabis use has led to legal, financial, or health problems
• You are using cannabis daily or near-daily
• You are an adolescent or young adult under 25 who is using cannabis regularly

Q: Is marijuana addictive?

A: Yes. Despite a persistent myth that cannabis is not addictive, research clearly demonstrates that approximately 22-30% of people who use cannabis develop cannabis use disorder (NIDA). The risk is even higher for adolescents, with approximately 1 in 6 teen users developing CUD (AACAP). The DSM-5 recognizes cannabis use disorder as a diagnosable mental health condition with formal criteria for tolerance, withdrawal, craving, and loss of control. Cannabis acts on the brain's reward system through the endocannabinoid system, and chronic use produces neuroadaptive changes that underlie addiction.

Q: What are the symptoms of cannabis withdrawal?

A: Cannabis withdrawal is a recognized DSM-5 diagnosis that affects approximately 12.1% of frequent users. Symptoms typically begin within 24-72 hours of cessation and can last 1-2 weeks. The most common symptoms include irritability and anger, insomnia and sleep disturbance, decreased appetite and weight loss, anxiety and restlessness, depressed mood, and intense cravings for cannabis. Some individuals also experience physical symptoms such as abdominal pain, sweating, fever, chills, and tremors. While not medically dangerous, cannabis withdrawal can be highly uncomfortable and is a common trigger for relapse.

Q: How is cannabis use disorder diagnosed?

A: CUD is diagnosed by a qualified clinician using the DSM-5 criteria. The evaluation assesses whether the patient meets at least 2 of 11 specific criteria within a 12-month period. These criteria span four domains: impaired control (using more than intended, inability to cut down, excessive time spent, craving), social impairment (failure to fulfill obligations, interpersonal problems, giving up activities), risky use (use in hazardous situations, use despite known harm), and pharmacological indicators (tolerance and withdrawal). Severity is classified as mild (2-3 criteria), moderate (4-5), or severe (6+).

Q: What treatments are available for cannabis use disorder?

A: The primary evidence-based treatments for CUD are behavioral therapies. Cognitive Behavioral Therapy (CBT) helps individuals identify triggers and develop coping strategies. Motivational Enhancement Therapy (MET) builds internal motivation to change. Contingency Management provides tangible rewards for maintaining abstinence. Research shows that combining these approaches produces better outcomes than any single therapy alone. There are currently no FDA-approved medications specifically for CUD, though several are under investigation, including N-acetylcysteine, gabapentin, and nabiximols. Treatment retention remains a challenge -- only 36.8% of adolescents completed CUD treatment between 2018-2021 (TEDS).

Q: How common is cannabis use disorder?

A: CUD is more common than most people realize. NIDA estimates that 22-30% of cannabis users -- roughly 3 in 10 -- develop the disorder. Among adolescents, the rate is approximately 1 in 6 users (AACAP). According to TEDS 2023, marijuana accounts for 9.8% of all substance use treatment admissions in the United States, making it the third most common substance behind alcohol and opioids. The prevalence of CUD has been increasing in recent years alongside rising THC potency and expanding legalization.

Q: Can you develop cannabis use disorder from occasional use?

A: While the risk of CUD is highest among daily or near-daily users, it is possible for occasional users to develop the disorder, particularly when other risk factors are present. Key risk factors include early age of first use (especially before age 15), family history of substance use disorders, co-occurring mental health conditions such as anxiety, depression, or PTSD, use of high-potency THC products (concentrates, dabs), and using cannabis as a primary coping mechanism for stress or emotional distress. The progression from casual to problematic use is often gradual, making it difficult to recognize without honest self-evaluation or external feedback from people close to the user.

Concerned About Your Cannabis Use?

Dr. Ryan Sultan provides evidence-based evaluation and treatment for cannabis use disorder. As an NIH NIDA-funded researcher at Columbia University, he brings both clinical expertise and cutting-edge research knowledge to every patient interaction.

Telehealth appointments available | Board-Certified Psychiatrist | Columbia University Faculty